Moventig (Naloxegol)

Naloxegol, the active ingredient in Moventig, is a peripherally acting mu‑opioid receptor antagonist (PAMORA) presented as an oral dosage form for oral use. It treats opioid‑induced constipation in patients receiving opioid therapy, helping to restore normal bowel function without affecting analgesia. GNH USA supplies Moventig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable distribution across multiple regions.

Naloxegol is indicated for opioid‑induced constipation, a condition resulting from opioid therapy that impairs gastrointestinal motility.

- Opioid‑induced constipation in chronic non‑cancer pain: improves bowel movements and reduces the need for laxatives. - Opioid‑induced constipation in cancer pain: alleviates constipation while maintaining analgesic effect. - Opioid‑induced constipation in postoperative pain management: restores normal intestinal transit in patients receiving opioids after surgery.

Commonly reported adverse reactions with naloxegol are generally mild and transient, while rare events may be serious.

Common Side Effects: - Abdominal pain - Diarrhea - Nausea - Flatulence - Headache - Vomiting

Serious or Rare Side Effects: - Intestinal obstruction or severe abdominal pain - Allergic reactions including rash, pruritus, or anaphylaxis - Pancreatitis - Severe hepatic injury - Ischemic colitis

When prescribing naloxegol, clinicians should consider several safety precautions to minimize risk.

- Renal function assessment: evaluate creatinine clearance before initiating therapy. - Hepatic impairment: avoid use in patients with severe liver disease (Child‑Pugh C). - Gastrointestinal obstruction risk: do not use in patients with known or suspected bowel obstruction. - Concomitant strong CYP3A4 inhibitors: avoid co‑administration as it may increase drug exposure. - Monitoring for abdominal symptoms: advise patients to report persistent or worsening abdominal pain. - Store below 25°C: keep in the original pack, protect from moisture.

Naloxegol may interact with other medicines that affect its metabolism or gastrointestinal motility.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): may markedly increase naloxegol plasma levels. - Concomitant use with other PAMORAs: can lead to additive effects and increased adverse events.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may require dose adjustment or close monitoring. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce naloxegol efficacy. - Antidiarrheal agents (e.g., loperamide): may mask symptoms of constipation improvement.